Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric cemiplimab study in relapsed or refractory solid/CNS tumors and with radiotherapy in glioma
2023-000604-19Phase 2
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of cemiplimab in Nonhematologic neoplasms, central nervous system tumor, diffuse intrinsic pontine glioma (DIPG) and 1 more (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Incidence and severity of treatment-emergent adverse events.
02
Drugs
cemiplimab
03
Conditions
Nonhematologic neoplasmscentral nervous system tumordiffuse intrinsic pontine glioma (DIPG)glioma
Beyond the preview
Go deeper on 2023-000604-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000604-19.